Your browser doesn't support javascript.
loading
Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.
Matsuo, Naoki; Morita, Tatsuya; Matsuda, Yoshinobu; Okamoto, Kenichiro; Matsumoto, Yoshihisa; Kaneishi, Keisuke; Odagiri, Takuya; Sakurai, Hiroki; Katayama, Hideki; Mori, Ichiro; Yamada, Hirohide; Watanabe, Hiroaki; Yokoyama, Taro; Yamaguchi, Takashi; Nishi, Tomohiro; Shirado, Akemi; Hiramoto, Shuji; Watanabe, Toshio; Kohara, Hiroyuki; Shimoyama, Satofumi; Aruga, Etsuko; Baba, Mika; Sumita, Koki; Iwase, Satoru.
  • Matsuo N; Hospice, Medical Corporation Junkei-kai Sotoasahikawa Hospital, Sotoasahikawa, Akita, Akita, Japan. Electronic address: matsuo@jkk-sotohp.or.jp.
  • Morita T; Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan.
  • Matsuda Y; Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan.
  • Okamoto K; Palliative Medicine, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan.
  • Matsumoto Y; Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Kaneishi K; Department of Palliative Care Unit, JCHO Tokyo Shinjuku Medical Center, Shinjuku, Tokyo, Japan.
  • Odagiri T; Komaki City Hospital, Komaki City, Aichi, Japan.
  • Sakurai H; Department of Palliative Care and Pain Management, Cancer Institute Hospital, Koto-ku, Tokyo, Japan.
  • Katayama H; NHO Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan.
  • Mori I; Gratia Hospital Hospice, Mino, Osaka, Japan.
  • Yamada H; Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Watanabe H; Komaki City Hospital, Komaki, Aichi, Japan.
  • Yokoyama T; Department of Palliative Medicine, Yokohama Municipal Citizens Hospital, Yokohama, Kanagawa, Japan.
  • Yamaguchi T; Department of Palliative Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Nishi T; Kawasaki Municipal Ida Hospital, Kawasaki, Kanagawa, Japan.
  • Shirado A; Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Hiramoto S; Department of Oncology, Mitsubishi Kyoto Hospital, Nisikyo-ku, Kyoto, Japan.
  • Watanabe T; Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
  • Kohara H; Department of Palliative Care, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan.
  • Shimoyama S; Department of Palliative Care, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan.
  • Aruga E; Department of Palliative Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
  • Baba M; Palliative Care Division, Saito Yukoukai Hospital, Ibaragi, Osaka, Japan.
  • Sumita K; Matsue City Hospital, Matsue, Shimane, Japan.
  • Iwase S; Research Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
J Pain Symptom Manage ; 52(1): 64-72, 2016 07.
Article en En | MEDLINE | ID: mdl-27233138
ABSTRACT
CONTEXT Although corticosteroids are widely used to relieve cancer-related fatigue (CRF), information regarding the factors predicting responses to corticosteroids remains limited.

OBJECTIVES:

The aim of this study was to identify potential factors predicting responses to corticosteroids for CRF in advanced cancer patients.

METHODS:

Inclusion criteria for this multicenter, prospective, observational study were patients who had metastatic or locally advanced cancer and had a fatigue intensity score of 4 or more on a 0-10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting two-point reduction or more in NRS on day 3.

RESULTS:

Among 179 patients who received corticosteroids, 86 (48%; 95% CI 41%-56%) had a response with two-point reduction or more. Factors that significantly predicted responses were performance status score of 3 or more, Palliative Performance Scale score more than 40, absence of ascites, absence of drowsiness, absence of depression, serum albumin level greater than 3 mg/dL, serum sodium level greater than 135 mEq/L, and baseline NRS score greater than 5. A multivariate analysis showed that the independent factors predicting responses were baseline NRS score greater than 5 (odds ratio [OR] 6.6, 95% CI 2.8-15.4), Palliative Performance Scale score more than 40 (OR 4.4, 95% CI 2.1-9.3), absence of drowsiness (OR 3.4, 95% CI 1.7-6.9), absence of ascites (OR 2.3, 95% CI 1.1-4.7), and absence of pleural effusion (OR 2.2, 95% CI 1.0-5.0).

CONCLUSION:

Treatment responses to corticosteroids for CRF may be predicted by baseline symptom intensity, performance status, drowsiness, and severity of fluid retention symptoms. Larger prospective studies are needed to confirm these results.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Fatiga / Estimulantes del Sistema Nervioso Central / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Fatiga / Estimulantes del Sistema Nervioso Central / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article